Synonyms: STX478
Compound class:
Synthetic organic
Comment: STX-478 (formerly ST-814; Scorpion Therapeutics) is an oral, CNS-penetrant PI3Kα allosteric inhibitor, that is intended for treatment of cancers with oncogenic PI3Kα mutations (e.g. H1047X substitutions).
The chemical structure shown here was revealed during the First Time Disclosures session at the ACS meeting in September 2023, and we picked it up from Drug Hunter. The discovery of STX-478 (including its structure) was formally disclosed in a Cancer Discovery article by Buckbinder et al. (2023) [1]. Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Additional PI3Kα inhibitors are claimed in Scorpion Therapeutics' 2023 patent WO2023018636A1 [2]. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|